Top

Published in:

Open Access 01-12-2018 | Letter

Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?

Authors: Patrick M. Honore, David De Bels, Leonel Barreto Gutierrez, Sebastien Redant, Rachid Attou, Andrea Gallerani, Herbert D. Spapen

Published in: Critical Care | Issue 1/2018

Excerpt

We applaud the recent work of Maseda et al. [1] and the additional comments of Agrifoglio et al. [2] which offer insight into optimizing micafungin treatment in obese patients and in patients with burn injury. We would like to draw attention to another group of critically ill patients who might benefit from dose adaptation of micafungin, i.e., those undergoing continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO). …

Maseda E, Grau S, Luque S, et al. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. Crit Care. 2018;22:94.CrossRef

Agrifoglio A, Cachafeiro L, Herrero E, Sánchez M, García de Lorenzo A. Are we near to the end of the standard dose of micafungin? Crit Care. 2018;22:149.CrossRef

Vossen MG, Knafl D, Haidinger M, et al. Micafungin plasma levels are not affected by continuous renal replacement therapy: Experience in critically ill patients. Antimicrob Agents Chemother. 2017;61(8). pii: e02425-16. https://doi.org/10.1128/AAC.02425-16.

Watt KM, Cohen-Wolkowiez M, Williams DC, et al. Antifungal extraction by the extracorporeal membrane oxygenation circuit. J Extra Corpor Technol. 2017;49:150–9.PubMedPubMedCentral

Mourvilliers B, Julien V, Trouillet JL et al. Increase micafungin dose for patients under ECMO. 27^th ECCMID. Vienna April 22–25; 2017. (Abstract) https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=41013.

Title: Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?
Authors: Patrick M. Honore
David De Bels
Leonel Barreto Gutierrez
Sebastien Redant
Rachid Attou
Andrea Gallerani
Herbert D. Spapen
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Critical Care / Issue 1/2018
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-018-2231-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Can a simple chemical help to both prevent and treat sepsis

Intrapulmonary autologous transplant of bone marrow-derived mesenchymal stromal cells improves lipopolysaccharide-induced acute respiratory distress syndrome in rabbit

Variation of poorly ventilated lung units (silent spaces) measured by electrical impedance tomography to dynamically assess recruitment

Categorization of post-cardiac arrest patients according to the pattern of amplitude-integrated electroencephalography after return of spontaneous circulation

Urinary biomarkers predict advanced acute kidney injury after cardiovascular surgery

Could ultrasound-guided internal jugular vein catheter insertion replace the use of chest X-ray?